BioSpace News Archive

Bausch Health Companies Inc. today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev.

Ligand Pharmaceuticals Incorporated announced the completion of its expected tax-free distribution of 100% of Ligand’s interest in its subsidiary OmniAb on a pro rata basis to Ligand shareholders of record as of October 26, 2022.

Nascent Biotech, Inc. announced today that the United States Patent and Trademark Office will issue patent No. 11,492,394 on November 8, 2022 for claims related to the Company’s lead candidate Pritumumab.

Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the third quarter ended September 30, 2022.

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced four development programs that target fundamental pathways of cellular energetics.

T2 Biosystems, Inc. today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on October 31, 2022 informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market.

Quoin Pharmaceuticals Ltd. announced today that its third quarter 2022 financial results will be reported on Thursday, November 10, 2022 before the open of the financial markets.

Biotricity Inc. today announced it will host a conference call on Monday, November 14, 2022 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 second quarter and provide a business update.

Cognitive Research Corporation a leading, full-service, therapeutically-focused Contract Research Organization specializing in the Central Nervous System sector, is pleased to announce that Jeff Williams has been appointed as Executive Chairman of the Board of Directors following the recent close of a growth equity investment from healthcare-focused private equity firm, RC Capital.

INVO Bioscience, Inc. (NASDAQ: INVO) today announced a successful showcasing of INVOcell at last week’s 2022 Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) held on October 22-26, 2022 in Anaheim, California.